Listed on the Emerging Stock Board, classified under Healthcare. This page collects the company's annual reports and investor conference materials, with files served directly by the Market Observation Post System (MOPS).
Taiwanese listed companies hold investor conferences (法人說明會) to present quarterly results. Presentation decks are filed with MOPS, most in both languages.
(1)本公司受邀於2025年第九屆脂肪肝炎藥物開發高峰會(9th MASH Drug Development Summit)進行SNP-6藥物及非侵入性生物指標臨床數據發表。 (2)脂肪肝炎藥物開發高峰會是全球最負盛名的代謝性脂肪肝炎藥物開發會議，會議內容聚焦代謝相關脂肪肝炎的基礎研究、藥物開發進展、臨床試驗設計相關議題，包括Eli Lilly, AstraZeneca, Pfizer, Madrigal, Bristol Myers Squibb…等世界級大廠的重要人士均會參加此高峰會，為與會者提供與行業領袖和同行交流合作的機會以促進合作。 (3)本公司受邀於本次峰會中以口頭演講及壁報論文方式發表多靶點候選藥物SNP-6藥物的安全性與療效數據，內容涵蓋多項非侵入式指標診斷MASH嚴重程度之研究成果，展現對未被滿足醫療需求（unmet medical need）的回應，機會誠屬難得。
Agenda as filed by the company, in Chinese only.
Every financial year in the table above links straight to the PDF filed with the Market Observation Post System (MOPS), Taiwan's statutory disclosure platform. 2 years are available in English, within a range covering 2024 to 2025.
Filing an English annual report is only mandatory for larger Taiwanese issuers; smaller companies and those on the Emerging Stock Board file in Chinese. Where no English edition exists this site links the Chinese PDF rather than leaving the year blank, so you can still reach the document.
It is the Taiwanese equivalent of an earnings call or analyst briefing. Listed companies present quarterly results and outlook, and file the presentation deck with MOPS — usually in both Chinese and English. Many also publish a webcast recording.
Taiwanese issuers file quarterly financial reports plus an annual report, and publish monthly revenue figures — a disclosure cadence that is more frequent than Hong Kong or Singapore. Financial years are numbered using the ROC calendar (ROC 114 = 2025); this site shows both.
